Objective: To estimate the prevalence of and risk factors for cardiovascular autonomic neuropathy (CAN) in adolescents and young adults with type 1 and type 2 diabetes enrolled in the SEARCH for Diabetes in Youth Study.
| INTRODUCTION
Cardiovascular autonomic neuropathy (CAN) is a serious complication of diabetes affecting the autonomic nerves innervating the heart and blood vessels, with subsequent sympathovagal imbalance and impact on heart rate regulation and cardiac performance. [1] [2] [3] Although asymptomatic in earlier stages, CAN has been shown to be an independent predictor of cardiovascular disease (CVD) mortality risk, 4 ,5 silent myocardial ischemia 6 and/or major CVD events, 7 cardiac remodeling and left ventricular dysfunction, 8 and progression of diabetic nephropathy and chronic kidney disease. 9 ,10 Yet, CAN is one of the least recognized complications of diabetes, especially in youth.
Reduction in the heart rate variability (HRV) parameters is the earliest manifestations of CAN. Evaluation of HRV with time and frequency domain indices are non-invasive methods to assess the presence and severity of CAN. 2 Several small cross-sectional studies in various pediatric populations, using diverse definitions, have reported CAN prevalence estimates between 18% and 75%. [11] [12] [13] [14] [15] In one of the largest pediatric epidemiological studies assessing the burden of diabetes-related complications in an Australian cohort of adolescents with diabetes, Eppens et al found strikingly high prevalence of autonomic neuropathy (using pupillometry) in adolescents with type 1 and type 2 diabetes (61% and 57%, respectively). 15 Apart from the SEARCH study, there have been no systematic efforts to assess the burden of neuropathy, including CAN, in adolescents and young adults with diabetes in the United States. We previously reported that youth with type 1 diabetes have reduced HRV as compared to age-matched healthy controls enrolled in the SEARCH CVD study. 16 Although, we have recently reported the age-adjusted prevalence of several diabetic complications (including CAN) in the SEARCH participants as part of the SEARCH Cohort Study, 17 the specific objective of this study was to examine the prevalence of CAN more closely by age group, diabetes duration, gender and race/ethnicity. Moreover, we were specifically interested in examining the cross-sectional and longitudinal risk factors (since diagnosis of diabetes to present) in adolescents and young adults with type 1 and type 2 diabetes to better understand the underlying risk factors and the pathological processes that drive CAN in this young cohort.
The overall objectives of the current study were: (1) 
| Study population
Adolescents and young adults with diabetes diagnosed at <20 years of age were identified from a population-derived incident registry network at 5 US sites by the SEARCH for Diabetes in Youth Registry
Study. 17 and those with incomplete neuropathy assessment (n = 305), which reduced the analytic sample size to 1898 individuals ( Figure A2 ).
Prior to protocol implementation, local institutional review board approval was obtained for each center. Written informed consent was obtained from participants 18 years and older, while assent with parental written informed consent was obtained for participants younger than 18 years.
| Baseline and cohort visits
The SEARCH baseline and cohort visits included a participant survey; measurement of height, weight, waist circumference, blood pressure;
and blood and urine collection. Race and ethnicity were self-reported and categorized as non-Hispanic White (NHW), non-Hispanic Black (NHB), Hispanic, Asian or Pacific Islander, and Other. Current cigarette smoking was defined as having smoked cigarettes on ≥1 of the 30 days preceding the visit. Individuals who had tried smoking or smoked regularly (at least 1 cigarette every day for 30 days) but were not current smokers were considered former smokers. Subjects who had never smoked a whole cigarette were considered non-smokers.
Waist circumference was measured using the natural waist location 17 and divided by height in centimeters to calculate the waist-toheight ratio (WHR). Body mass index (BMI) was defined as weight (kg) divided by height 2 (m). For participants <20 years of age, the Centers for Disease Control and Prevention (CDC)-derived BMI z20 scores were used; for those ≥20 years the observed mean and SD were used to standardize their BMI z20 values.
Resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 3 times using an aneroid sphygmomanometer while the participants were seated for at least 5 minutes, and the average of the 3 measurements was taken.
A blood draw occurred after an 8-hour overnight fast, and medications, including short-acting insulin, were withheld the morning of the visit. Blood samples were obtained under conditions of metabolic stability, as defined by no episodes of diabetic ketoacidosis in the prior month.
Specimens were processed locally at the sites and shipped within 24 hours to the central laboratory (Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington), where they were analyzed for measurement of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and glycated hemoglobin (HbA1c) as previously described. 17 Urinary albumin and creatinine levels were assessed on a random spot urine sample to evaluate renal function using the albumin-to-creatinine ratio (ACR 
| Longitudinal data
In addition to the data collected at the baseline and cohort visit, the area under the curve (AUC) was computed to summarize the longitudinal trajectory of HbA1c and other continuous variables, such as lipids, blood pressure, and BMI collected over time (at the baseline, 1-, 2-, or 5-year follow-up and cohort visits), adjusting for the time interval between the first and last measurement.
To assess the association of long-term glycemic control with CAN, logistic regression models treating the presence of CAN as the outcome were fitted separately for participants with type 1 and type 2 diabetes. These models were adjusted for potential confounders (collected at current SEARCH cohort visit) such as age and sex (Model 2), BMI (Model 3), blood pressure (Model 4), triglycerides (Model 5), and ACR (Model 6). A fully adjusted model that included all of these variables as covariates was also fitted (Model 7). Models were stratified by diabetes type to limit confounding effects of age and adiposity. Diagnostic tests were performed to ensure that modeling assumptions were satisfied. The data were analyzed using SAS 9.4 (SAS Institute, Cary, NC).
| RESULTS
Characteristics of adolescents and young adults with type 1 (n = 1646) and type 2 diabetes (n = 252) stratified by their CAN status are shown in pared to those without CAN (all P < .05; Table 1 ). Hispanic and NHW subjects with type 2 diabetes had a higher prevalence of CAN (29% and 27%, respectively) as compared to NHB (7%) and other minority groups (12%) (P = .001).
The AUC for cardio-metabolic risk factors for CAN is depicted in Table 2 . Long-term poor glycemic control, summarized as AUC for HbA1c, triglyceride levels (AUC triglycerides), and blood pressure (AUC SBP and AUC DBP), were significantly higher among type 1 diabetes subjects with CAN as compared to those without CAN. Only higher triglycerides over time were significantly associated with CAN among subjects with type 2 diabetes ( Table 2) . Table 3 summarizes the results from the multiple logistic regression analyses for the association between longitudinal glycemic control (AUC HbA1c as the independent variable) and CAN (dependent variable) adjusted sequentially for covariates. Long-term poor glycemic control (AUC HbA1c) was associated with CAN independent of age, sex, blood pressure, BMI, triglyceride levels, and ACR in subjects with type 1 diabetes, but not in those with type 2 diabetes (Table 3) .
Since nearly 32% (n = 879) of the 2777 SEARCH participants
were excluded from the analysis dataset due to various reasons (age < 10 years, missing etiological definition of diabetes type, incomplete CAN assessment), we examined whether there were any significant differences in the anthropometric, demographic, and metabolic characteristics of the participants who were excluded vs included in this dataset that could potentially affect the prevalence estimates. Individuals excluded (n = 879) from the analysis were more likely to have a longer duration of diabetes (9 vs 8 years, P < .001) and were younger at the time of diabetes diagnosis (9 vs 11 years, P < .001), as compared to those included in the analytic sample (n = 1898) (Table A1 ). 15 However, in that cohort autonomic neuropathy was defined as an abnormal pupillometry test (assessed by measuring the pupil size before and 3 seconds after a light stimulus was delivered using an infrared pupillometer). 15 The difference in the method of assessment (pupillometry vs HRV testing) likely explains the higher prevalence of autonomic neuropathy in the Australian cohort, in spite of that cohort being younger, with shorter diabetes duration and better glycemic control compared with the SEARCH cohort. 15 Although pupillometry was considered in the past a simple non-invasive test to assess parasympathetic autonomic function, it has not been widely used in the research setting because of the lack of standardization in the techniques employed, and the lack of validation studies. Abbreviations: ACR, albumin:creatinine ratio; BMI, body mass index; CAN, cardiovascular autonomic neuropathy; CRP, C-reactive protein; LDL-C, lowdensity lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SBP and DBP, systolic and diastolic blood pressure. All data are presented as mean AE SD or n (%) or median (IQR).
| DISCUSSION
There is ample biologic plausibility and evidence for the causal role of hyperglycemia in the development and progression of chronic complications, including CAN. 1, [26] [27] [28] [29] Hyperglycemia induces abnormal signaling of the autonomic neurons via accumulation of advanced glycation end products and microangiopathy, causing ischemic atrophy of autonomic nerve fibers innervating cardiac and vascular tissues. 30 In this study, glucose control was quite poor in adolescents and young adults with type 1 or type 2 diabetes, with a mean HbA1c of~9%, far exceeding the target HbA1c (<7.5%) recommended by the American Diabetes Association. 31 These data further confirm that there is an urgent need for efforts focused at improving glycemic control among adolescents and young adults with diabetes to mitigate the elevated risk of the adverse outcomes associated with CAN and its downstream consequences, including increased CVD risk.
Dyslipidemia has also been implicated in the pathogenesis of diabetic neuropathy in a non-glucocentric paradigm involving linked metabolic and inflammatory insults that trigger neurodegeneration. [32] [33] [34] [35] [36] However, there is a close link between glucose and lipid metabolism, as hypertriglyceridemia and reduced HDL commonly occur in poorly controlled type 1 and type 2 diabetes. 33 Hyperglycemia and dyslipidemia are also known as pro-inflammatory triggers to the neurodegenerative processes. 23 In a prior analysis of youth participating in the SEARCH CVD study, we found an atherogenic lipid profile in youth with type 1 diabetes and reduced HRV as compared to age-matched healthy controls. 16 The findings from this study have important clinical implications.
We observed that youth and young adults with type 1 and type 2 diabetes have evidence of CAN, as documented by changes in HRV at a mean diabetes duration of 8 years. Emerging epidemiological evidence also suggests that CAN is associated with increased arterial stiffness in adolescents 37 and adults 38 with type 1 diabetes, and thus could have an additive effect on the risk of future cardiovascular events, which occur earlier and with poorer prognosis in individuals with diabetes compared with the general population. 4, 39, 40 Considering that SEARCH participants are a representative cohort of US youth with diabetes and have suboptimal glycemic control (mean HbA1c well above the American Diabetes Association recommended target of <7.5%), 19 these data provide evidence that screening for CAN, as is recommended for adults, may be beneficial in adolescents and young adults, 1 especially in those individuals who have additional risk factors associated with CAN. Recent recommendations from the American Heart Association call for a multifactorial approach to mitigate the increased CVD risk in youth with diabetes. 41 Thus, targeting poor glycemic control and dyslipidemia in adolescents and young adults with diabetes as early as possible, which is also in line with current standard of care in diabetes, 31 could help mitigate the increased CVD risk in this young population. 28, 36 The large sample size, multiethnic composition of the cohort, use of a non-invasive, simple, validated instrument to assess CAN, and evaluation of the longitudinal and cross-sectional risk factors are Abbreviations: AUC, area under the curve derived from data collected at baseline, 1-, 2-, 5-year follow-up and the current cohort visits; BMI, body mass index; CAN, cardiovascular autonomic neuropathy; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SBP and DBP, systolic and diastolic blood pressure. All data are presented as mean AE SD. among the strengths of our study. The limited power to examine the association between long-term glycemic control and CAN among persons with type 2 diabetes (despite similar levels of HbA1c to those with type 1 diabetes) could be due to a comparatively small sample size (although the association was in the same direction as that of the type 1 diabetes group) is one of the limitations of our study. The lack of longitudinal measures of CAN is also a limitation of our study, 
